异动解读 | Hims & Hers Health盘前大跌13.64%，因放弃49美元减肥药面临监管压力

异动解读02-09

远程医疗公司Hims & Hers Health Inc. (HIMS) 今日盘前股价大跌13.64%，引起了市场的广泛关注。

消息面上，此次股价下跌主要与公司最新业务决策有关。Hims & Hers于上周四宣布推出一款售价49美元的仿制减肥药，其基于诺和诺德重磅药物Wegovy的主要成分司美格鲁肽。然而，该举措迅速引来了原研药厂商诺和诺德以及美国食品药品监督管理局(FDA)的法律威胁与警告，认为该复方制剂可能非法。

面对监管压力，Hims & Hers于周六表示，在与相关利益方进行建设性对话后，已决定停止提供该疗法。市场分析认为，此举意味着公司一个潜在的重要增长产品线受阻，同时凸显了在GLP-1类药物领域面临的监管风险，从而导致了投资者信心受挫和股价大幅下挫。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1103889956?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-09 17:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103889956","market":"us","top_or_hot":-1,"title":"异动解读 | Hims & Hers Health盘前大跌13.64%，因放弃49美元减肥药面临监管压力","media":"异动解读","content":"<p>远程医疗公司Hims & Hers Health Inc. (HIMS) 今日盘前股价大跌13.64%，引起了市场的广泛关注。</p><p>消息面上，此次股价下跌主要与公司最新业务决策有关。Hims & Hers于上周四宣布推出一款售价49美元的仿制减肥药，其基于诺和诺德重磅药物Wegovy的主要成分司美格鲁肽。然而，该举措迅速引来了原研药厂商诺和诺德以及美国食品药品监督管理局(FDA)的法律威胁与警告，认为该复方制剂可能非法。</p><p>面对监管压力，Hims & Hers于周六表示，在与相关利益方进行建设性对话后，已决定停止提供该疗法。市场分析认为，此举意味着公司一个潜在的重要增长产品线受阻，同时凸显了在GLP-1类药物领域面临的监管风险，从而导致了投资者信心受挫和股价大幅下挫。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | Hims & Hers Health盘前大跌13.64%，因放弃49美元减肥药面临监管压力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | Hims & Hers Health盘前大跌13.64%，因放弃49美元减肥药面临监管压力\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-09 17:27 北京时间&nbsp;&nbsp;&nbsp;<strong>异动解读</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>远程医疗公司Hims & Hers Health Inc. (HIMS) 今日盘前股价大跌13.64%，引起了市场的广泛关注。消息面上，此次股价下跌主要与公司最新业务决策有关。Hims & Hers于上周四宣布推出一款售价49美元的仿制减肥药，其基于诺和诺德重磅药物Wegovy的主要成分司美格鲁肽。然而，该举措迅速引来了原研药厂商诺和诺德以及美国食品药品监督管理局(FDA)的法律威胁与警告，认为该...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1103889956","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103889956","pubTimestamp":1770629226,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"远程医疗公司Hims & Hers Health Inc.  今日盘前股价大跌13.64%，引起了市场的广泛关注。消息面上，此次股价下跌主要与公司最新业务决策有关。Hims & Hers于上周四宣布推出一款售价49美元的仿制减肥药，其基于诺和诺德重磅药物Wegovy的主要成分司美格鲁肽。面对监管压力，Hims & Hers于周六表示，在与相关利益方进行建设性对话后，已决定停止提供该疗法。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"Interpretation of changes | Hims & Hers Health fell 13.64% before the market, facing regulatory pressure due to abandoning the $49 diet pill","themeId":"f7c0bd47606c6d38ed63371867a97d11","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"远程医疗公司Hims & Hers Health Inc. (HIMS) 今日盘前股价大跌13.64%，引起了市场的广泛关注。消息面上，此次股价下跌主要与公司最新业务决策有关。Hims & Hers于上周四宣布推出一款售价49美元的仿制减肥药，其基于诺和诺德重磅药物Wegovy的主要成分司美格鲁肽。然而，该举措迅速引来了原研药厂商诺和诺德以及美国食品药品监督管理局(FDA)的法律威胁与警告，认为该复方制剂可能非法。面对监管压力，Hims & Hers于周六表示，在与相关利益方进行建设性对话后，已决定停止提供该疗法。市场分析认为，此举意味着公司一个潜在的重要增长产品线受阻，同时凸显了在GLP-1类药物领域面临的监管风险，从而导致了投资者信心受挫和股价大幅下挫。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103889956","isCrawlerRequest":true}